JP2019535754A5 - - Google Patents

Download PDF

Info

Publication number
JP2019535754A5
JP2019535754A5 JP2019527426A JP2019527426A JP2019535754A5 JP 2019535754 A5 JP2019535754 A5 JP 2019535754A5 JP 2019527426 A JP2019527426 A JP 2019527426A JP 2019527426 A JP2019527426 A JP 2019527426A JP 2019535754 A5 JP2019535754 A5 JP 2019535754A5
Authority
JP
Japan
Prior art keywords
formula
compound according
compound
pharmaceutically acceptable
equation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019527426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535754A (ja
JP7167021B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/063182 external-priority patent/WO2018098390A1/en
Publication of JP2019535754A publication Critical patent/JP2019535754A/ja
Publication of JP2019535754A5 publication Critical patent/JP2019535754A5/ja
Application granted granted Critical
Publication of JP7167021B2 publication Critical patent/JP7167021B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019527426A 2016-11-23 2017-11-24 アルブミン結合psma阻害剤 Active JP7167021B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425810P 2016-11-23 2016-11-23
US62/425,810 2016-11-23
PCT/US2017/063182 WO2018098390A1 (en) 2016-11-23 2017-11-24 Albumin-binding psma inhibitors

Publications (3)

Publication Number Publication Date
JP2019535754A JP2019535754A (ja) 2019-12-12
JP2019535754A5 true JP2019535754A5 (cg-RX-API-DMAC7.html) 2021-01-07
JP7167021B2 JP7167021B2 (ja) 2022-11-08

Family

ID=60812130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019527426A Active JP7167021B2 (ja) 2016-11-23 2017-11-24 アルブミン結合psma阻害剤

Country Status (8)

Country Link
US (1) US11147889B2 (cg-RX-API-DMAC7.html)
EP (1) EP3544960A1 (cg-RX-API-DMAC7.html)
JP (1) JP7167021B2 (cg-RX-API-DMAC7.html)
CN (1) CN109982998A (cg-RX-API-DMAC7.html)
BR (1) BR112019010206A2 (cg-RX-API-DMAC7.html)
CA (1) CA3043619A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019005742A (cg-RX-API-DMAC7.html)
WO (1) WO2018098390A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102884167B1 (ko) * 2017-10-22 2025-11-12 프로빈셜 헬스 서비시즈 오쏘리티 전립선 특이적 막 항원-발현 암의 진단 또는 치료를 위한 신규한 라디오메탈-결합 화합물
WO2019246445A1 (en) * 2018-06-20 2019-12-26 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
EP3880253A1 (en) * 2018-11-14 2021-09-22 Noria Therapeutics, Inc. Thioamide-containing compositions and methods of use thereof
WO2020108753A1 (en) * 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
US12472272B2 (en) 2019-04-17 2025-11-18 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer
CN119431260A (zh) 2019-06-21 2025-02-14 省卫生服务机构 靶向前列腺特异性膜抗原的放射性标记化合物
EP4116306A4 (en) 2020-03-04 2024-05-29 Nihon Medi-Physics Co., Ltd Compound and radioactive labeling compound
WO2021225760A1 (en) * 2020-05-06 2021-11-11 Cornell University Copper-containing theragnostic compounds and methods of use
US20240131206A1 (en) * 2020-12-04 2024-04-25 The Regents Of The University Of California Peptide receptor radionuclide therapy
EP4263509A4 (en) * 2020-12-16 2024-12-04 The University of British Columbia RADIOACTIVELY LABELLED COMPOUNDS FOR TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
KR20230154183A (ko) 2021-03-04 2023-11-07 니혼 메디피직스 가부시키가이샤 화합물 및 방사성 표지 화합물
US20250186627A1 (en) * 2022-03-04 2025-06-12 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
WO2024126687A1 (en) * 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety
EP4667019A1 (en) * 2023-02-16 2025-12-24 Norroy Bioscience Co., Ltd. Psma-targeted radiopharmaceutical, and synthesis and use thereof
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
CA3035532C (en) * 2009-03-19 2021-10-26 The Johns Hopkins University Psma-targeting compounds and uses thereof
HUE045028T2 (hu) * 2011-08-05 2019-12-30 Molecular Insight Pharm Inc Radiojelzett prosztataspecifikus membrán antigén inhibitorok
WO2013028664A1 (en) * 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
CA2929651A1 (en) * 2013-11-06 2015-05-14 Solstice Biologics, Ltd. Polynucleotide constructs having disulfide groups
US20160287731A1 (en) * 2013-11-14 2016-10-06 Endocyte, Inc. Compounds for Positron Emission Tomography
EP3183236B1 (en) * 2014-08-24 2022-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
AU2016333334B2 (en) * 2015-09-30 2019-07-25 Deutsches Krebsforschungszentrum 18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
WO2017165473A1 (en) * 2016-03-22 2017-09-28 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
JP7317505B2 (ja) * 2016-06-23 2023-07-31 コーネル ユニバーシティー 腫瘍死滅に影響する二重標的構築物
DE102016122273B4 (de) * 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung

Similar Documents

Publication Publication Date Title
JP2019535754A5 (cg-RX-API-DMAC7.html)
CN101668547B (zh) 选择缺氧组织的弱碱性2-硝基咪唑递送剂及其应用方法
US8435489B2 (en) Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
JP2018058847A5 (cg-RX-API-DMAC7.html)
JP2014510729A5 (cg-RX-API-DMAC7.html)
JP2006501149A5 (cg-RX-API-DMAC7.html)
JP2018199694A5 (cg-RX-API-DMAC7.html)
RU2011146362A (ru) Набор для предварительного таргетинга, способ и средства, используемые в нем
JP2019535754A (ja) アルブミン結合psma阻害剤
JP2010523599A5 (cg-RX-API-DMAC7.html)
WO2008124651A3 (en) Nitro-imidazole hypoxia imaging agents
JP2013521287A5 (cg-RX-API-DMAC7.html)
JP2010511704A5 (cg-RX-API-DMAC7.html)
CA3030907A1 (en) Chelated psma inhibitors
JP2015528814A5 (cg-RX-API-DMAC7.html)
CA2722858C (en) Substrate based pet imaging agents
JP2013504590A5 (cg-RX-API-DMAC7.html)
JP2009538894A5 (cg-RX-API-DMAC7.html)
JP2013507345A5 (cg-RX-API-DMAC7.html)
Subbarayan et al. Evaluation studies of technetium-99m-porphyrin (T3, 4BCPP) for tumor imaging
Welch et al. Production of non-standard PET radionuclides and the application of radiopharmaceuticals labeled with these nuclides
JP2024542261A (ja) 診療に寄与する新規ホウ素リポソーム
JP2018511648A5 (cg-RX-API-DMAC7.html)
US20090028791A1 (en) Dichloroacetate Analogs as Imaging Agents
Sartor et al. Stromal targeted therapy in bone metastatic prostate cancer: promise delivered